Celgene Corp.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen, Inc. -0.12%240.041.3%$790.04m
MRNAModerna, Inc. 5.68%68.870.0%$727.46m
IMMUImmunomedics, Inc. -0.14%85.1811.0%$688.17m
NVAXNovavax, Inc. 11.64%114.3696.5%$625.62m
GILDGilead Sciences, Inc. -0.47%61.961.0%$572.29m
ILMNIllumina, Inc. 3.84%297.303.5%$522.23m
REGNRegeneron Pharmaceuticals, Inc. 0.61%560.872.7%$427.68m
BIIBBiogen, Inc. -0.37%269.051.6%$331.93m
VRTXVertex Pharmaceuticals, Inc. 0.13%263.481.9%$328.68m
ALXNAlexion Pharmaceuticals, Inc. 0.01%112.032.0%$278.26m
SRNESorrento Therapeutics, Inc. 3.75%9.531.5%$255.46m
EXASEXACT Sciences Corp. 3.94%98.0320.7%$241.20m
VXRTVaxart, Inc. 7.84%7.430.0%$214.14m
SGENSeattle Genetics, Inc. 1.49%182.116.0%$206.92m
MNTAMomenta Pharmaceuticals, Inc. 0.00%52.393.0%$197.85m

Company Profile

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.